Urokinase type plasminogen activator receptor expression in colorectal neoplasms

S Suzuki, Y Hayashi, Y Wang, T Nakamura, Y Morita, K Kawasaki, K Ohta, N Aoyama, S R Kim, H Itoh, Y Kuroda, W F Doe

Abstract

Background—The urokinase type plasminogen activator receptor (uPAR) may play a critical role in cancer invasion and metastasis.

Aims—To study the involvement of uPAR in colorectal carcinogenesis.

Methods—The cellular expression and localisation of uPAR were investigated in colorectal adenomas and invasive carcinomas by in situ hybridisation, immunohistochemistry, and northern and western blot analyses.

Results—uPAR mRNA expression was found mainly in the cytoplasm of dysplastic epithelial cells of 30% of adenomas with mild (19%), moderate (21%), and severe (47%) dysplasia, and in that of carcinomatous cells of 85% of invasive carcinomas: Dukes’ stages A (72%), B (93%), and C (91%). Some stromal cells in the adjacent neoplastic epithelium were faintly positive. Immunoreactivity for uPAR was detected in dysplastic epithelial cells of 14% of adenomas and in carcinomatous cells of 49% of invasive carcinomas. uPAR mRNA and protein concentrations were significantly higher in severe than in mild or moderate dysplasia (p<0.05); they were notably higher in Dukes’ stage A than in severe dysplasia (p<0.05), and significantly higher in Dukes’ stage B than in stage A (p<0.05), but those in stage B were not different from those in stage C or in metastatic colorectal carcinomas of the liver.

Conclusions—Colorectal adenoma uPAR, expressed essentially in dysplastic epithelial cells, was upregulated with increasing severity of atypia, and increased notably during the critical transition from severe dysplastic adenoma to invasive carcinoma. These findings implicate uPAR expression in the invasive and metastatic processes of colorectal cancer.

(Gut 1998;43:798–805)

Keywords: urokinase type plasminogen activator receptor; colorectal adenoma; colorectal cancer; adenoma-carcinoma sequence

Recent studies suggest that cancer invasion and metastasis arise through a sequence, or an accumulation, of processes involving angiogenesis, adhesion, proteolysis, migration, and proliferation.1 2 These complex processes involve many interactions between cancer cells, components of the extracellular matrix, and a number of different molecules including proteolytic enzymes, adhesion molecules, and growth factors.3 5

Urokinase type plasminogen activator (uPA) is an extracellular serine protease that mediates focal proteolysis and contributes to cancer invasion and metastasis by catalysing conversion of plasminogen into plasmin, which degrades extracellular matrix (ECM) and activates latent proteases.4 5 uPA activation occurs on the cell surface after binding to its specific receptor (uPAR) and is regulated by the number of uPAR and the concentration of its specific inhibitors (PAIs), which include plasminogen activator inhibitor type 1 (PAI-1), type 2 (PAI-2), and proteinase nexin-1.10–14 Previous studies have implicated uPA activated cell surface activity in clinical behaviour of tumours as well as in tumour invasion and metastasis, especially in colorectal cancer. uPA content is significantly higher in adenomatous polyps and carcinomas than in normal mucosa,15 16 and uPA mRNA has been localised in stromal cells.30–32 PAI-1 mRNA is located in endothelial cells in the tumour stroma,33 and the activity and antigen levels of both PAI-1 and PAI-2 also increase in adenomatous polyps and carcinomas.30 31 41 42

Among the molecular components of the uPA system, uPAR expression on the surface of tumour cells seems to be central to the invasion process. The expression of uPAR has been reported in colon cancer19 43 and other types of malignancies,14 16 18–23 44 and has been shown to facilitate extracellular matrix invasion by colon cancer.17 45–47 Experimental evidence from in vitro and in vivo models also suggests a correlation between uPAR expression and cancer aggressiveness involving tumour growth, invasiveness, and metastasis.48–50 Furthermore, the functions of uPA have recently been investigated with regard to cell attachment and migration during the overall process of invasion and metastasis.51–56

It is widely accepted that the majority of colorectal carcinomas arise from adenomatous polyps of malignant potential.57 Various genetic changes with epithelial dysplasia have been shown in adenomas. Regarding the uPA system, several studies have reported that uPA expression and proteolytic activity increased in parallel with the sequence of normal mucosa–adenoma–carcinoma in colon.58–65 The relation between uPAR expression and carcinogenesis, however, remains to be shown.

In this study, we have analysed colorectal neoplasms representing the progression of the adenoma–carcinoma sequence from mild dys-
Plasminogen activator receptor expression in colorectal neoplasm

plasia through to carcinoma in situ. We have studied invasive cancer and metastasis by qualitative and quantitative techniques for uPAR gene transcript and protein, and report the significance of uPAR expression during the development of colorectal cancer.

Materials and methods

Tissue samples were collected after surgical or endoscopic resection. Tumour and normal tissues were divided in two: one part was frozen in liquid nitrogen and stored at −80°C for RNA and protein extraction; the other was fixed with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.0, at 4°C overnight. The samples were then dehydrated with a series of ethanol and defatted with chloroform and embedded in paraffin. Longitudinal sections (4 µm thick) were cut and mounted on slides coated with 3-(triethoxysilyl)-propylamine (Merck, Darmstadt, Germany) for immunohistochemical staining and in situ hybridisation. Routine staining methods using haematoxylin and eosin were carried out in adjacent sections. All specimens were classified according to standard histological criteria.

One hundred specimens were classified as adenoma with various grades of dysplasia characterised by cells with hyperchromatic, crowded, elongated, and stratified nuclei, increasing mitotic activity, loss of nuclear polarity, decreasing mucus secretion, and changing of crypt structure. The diagnostic grade of the 100 adenomas, based on the most severely dysplastic area, was as follows: mild dysplasia (31), moderate dysplasia (33), and severe dysplasia (36) containing carcinoma in situ (20). Eighty specimens of invasive carcinoma were staged according to Dukes’ classification.

Northern blot analysis

Northern blot analysis was carried out by a modified non-radiographic method as previously described. Total RNA was purified from frozen samples with ISOGEN (Nippon Gene, Tokyo, Japan). Total RNA per lane (20 µg) was electrophoresed on 1% agarose gels containing 7.5% formaldehyde and transferred to nylon membranes (Nylon membranes positively charged, Boehringer Mannheim) by capillary action in 20× SSC (saline sodium citrate). The membranes were baked for 30 minutes at 120°C and prehybridised in prehybridisation buffer (0.5% SDS (sodium dodecyl sulphate), 5× SSC, 10× Denhardt’s solution, 10 mM Na2PO4, 50% formamide, 0.1 mg/ml sonicated salmon sperm DNA) for three hours at 50°C. The RNA was probed by hybridisation at 50°C with DIG labelled DNA probe under prehybridisation conditions overnight. The membranes were washed with 0.2× SSC containing 0.1% SDS (20 minutes at 68°C, twice), rinsed in DIG buffer 1, incubated with 1% Blocking Reagent (Boehringer Mannheim) in DIG buffer 1 for 60 minutes at room temperature, incubated with 0.5 ml antidigoxigenin alkaline phosphate conjugated antibody diluted 1/10 000 in DIG buffer 1 with 0.2% polyoxethylen(20)sorbitan monolaurate (Wako Pure Chemical Industries Ltd., Osaka, Japan) for 30 minutes at room temperature, then washed with DIG buffer 1 (15 minutes, twice) and rinsed with DIG buffer 3 for three minutes. For detection of signals, the membranes were incubated at 37°C with CSPD (disodium 3,2’-(5’-chloro)tricloro(3.3.1.13,7)decan)-4-ly phenyl phosphate) (Boehringer Mannheim) diluted 1/100 in assay solution (100 mM diethanolamine, 2 mM MgCl2, 0.02% NaN3) for 10 minutes. Hybridisation signals were exposed to x ray film (Hyperfilm-ECL, Amersham) for three hours at room temperature. After hybridisation, the blots were stripped and rehybridised with β actin cDNA probe. The bands for uPAR mRNA were quantified with

IN SITU HYBRIDISATION

The in situ hybridisation techniques were carried out as previously described. Hybridisation of uPAR mRNAs was done at 50°C for 16 hours, and the signals were detected using a Nucleic Acid Detection Kit (Boehringer Mannheim Biochemica). The slides were counterstained with haematoxylin.

The control included: hybridisation with the sense probes; RNase treatment before hybridisation; and use of neither the antisense RNA probe nor the antidigoxigenin antibody. The three control experiments yielded no detectable signals. Expression and distribution of signals were evaluated by two observers (SS, TN) independently and blindly, and confirmed by a third observer (YH).

Preparation of RNA and cDNA probes

Digoxigenin labelled single strand RNA probes were prepared with a DIG RNA Labelling Kit (Boehringer Mannheim GmbH Biochemica, Mannheim, Germany) according to the manufacturer's instructions for in situ hybridisation. For generating the human uPAR probe, the 585 bp BamH1 and 268 bp PstI fragments of the uPAR cDNA clone were subcloned into the Vector pGEM-3Z (Promega, Wisconsin, USA). These plasmids were linearised with either HindIII and transcribed with T7 RNA polymerase to generate an antisense (cRNA) probe, or with EcoRI (for the 585 bp BamH1 fragment) or AccI (for the 268 bp PstI fragment) and transcribed with SP6 RNA polymerase to generate a sense probe. To acquire DIG labelled cDNA fragments as probes for northern blot analysis, the Vector pGEM-3Z subcloned by the 585 bp BamH1 fragment was amplified by polymerase chain reaction (PCR) with PCR DIG Probe Synthesi Kit (Boehringer Mannheim), using RNA polymerase promoter sequencing primers, T7 and SP6 (Promega).
Table 1  Expression of uPAR mRNA and protein in colorectal neoplasms

<table>
<thead>
<tr>
<th></th>
<th>Adenoma</th>
<th>Invasive carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mild dysplasia</td>
<td>Moderate dysplasia</td>
</tr>
<tr>
<td>In situ hybridisation (%)</td>
<td>6/31 (19)</td>
<td>7/33 (21)</td>
</tr>
<tr>
<td>Immunohistochemistry (%)</td>
<td>3/31 (10)</td>
<td>4/33 (12)</td>
</tr>
<tr>
<td>Northern blot analysis (%)</td>
<td>3/12 (25)</td>
<td>4/14 (29)</td>
</tr>
<tr>
<td>Western blot analysis (%)</td>
<td>3/13 (23)</td>
<td>3/14 (21)</td>
</tr>
</tbody>
</table>

*p<0.05 severe dysplasia versus moderate dysplasia.
†p<0.05 Dukes’ A versus severe dysplasia.
‡p<0.05 Dukes’ B versus Dukes’ A.

Figure 1  Localisation of uPAR gene transcript in colorectal neoplasms. (A) mild dysplasia: uPAR mRNA is present diffusely or focally in whole adenomas. (C) moderate dysplasia: uPAR mRNA shows mainly in the cytoplasm of dysplastic cells (arrowheads) and is faint in the cytoplasm of stromal cells (straight arrows) in adenomas. (E) invasive carcinoma: uPAR mRNA is strongly expressed in malignant cells on the surface of cancerous tissue, predominantly at the invasive front of the tumour (arrowheads). (B, D, F): no staining was detected with the sense riboprobe in adjacent sections.
Compared with Dukes’ stage A.

Results are expressed as mean (SEM). *p<0.05

Figure 3 Densitometric analysis. uPAR mRNA and protein concentrations seen on northern blots, normalised with 18S rRNA (1.86Kb) is indicated. (B) Representative western blot analysis of uPAR in extracts from colorectal neoplasms with antibody no. 3937. Lane 1, normal colorectal tissue; lanes 2, 3, 4, mild dysplasia; lanes 5, 6, moderate dysplasia; lanes 7, 8, severe dysplasia; lane 9, Dukes’ stage A carcinoma; lane 10, Dukes’ stage B carcinoma; lane 11, Dukes’ stage C carcinoma; lane 12, metastatic carcinoma of the liver. The position of 18S rRNA (1.86Kb) is indicated. (B) Representative western blot analysis of uPAR in extracts from colorectal neoplasms with antibody no. 3937. Lane 1, normal colorectal tissue; lanes 2, 3, 4, mild dysplasia; lanes 5, 6, moderate dysplasia; lanes 7, 8, severe dysplasia; lane 9, Dukes’ stage A carcinoma; lane 10, Dukes’ stage B carcinoma; lane 11, Dukes’ stage C carcinoma; lane 12, metastatic carcinoma of the liver. The relative position of molecular weight marker (kDa) is indicated on the left.

the software NIH Image 1.55 (National Institutes of Health, Bethesda, Maryland, USA).

IMMUNOHISTOCHEMISTRY

uPAR protein expression in tissue sections was localised immunohistochemically by the monoclonal antibody against human uPAR, no. 3937 (American Diagnostic Inc., Greenwich, Connecticut). Immunohistochemical staining was done with the Large Volume DAKO LSAB Kit, Peroxidase (Dakopatts, Copenhagen, Denmark) according to the manufacturer’s instructions. Formalin fixed sections (5 µm) were deparaffinised in xylene (five minutes, three times), then dehydrated in ethanol, and incubated with 3% hydrogen peroxide for 15 minutes, with blocking solution for

30 minutes and with monoclonal antibody, no. 3937 (American Diagnostic Inc.) diluted 1/100 in 0.01% PBS for two hours at room temperature. After washing with Tris buffer, the sections were visualised with aminoethylcarbazole chromogen containing hydrogen peroxide. The sections were counterstained with haematoxylin and mounted. The staining was evaluated by three observers as well as by in situ hybridisation. When all epithelial cells of one crypt or more than 20% of 500 epithelial cells in a section were stained, the neoplasm was scored as uPAR positive.

WESTERN BLOT ANALYSIS

Western blot analysis was carried out as previously described.46 Protein samples (40 µg) were subjected to 12.5% SDS polyacrylamide gel electrophoresis (PAGE), then electrotransferred onto nitrocellulose filters (Hybond-ECL, Amersham Corp.). The monoclonal antibody against human uPAR no. 3937 was used. Immunochemical detection was carried out with the enhanced chemiluminesence western blotting detection system (Amersham Corp.). Finally, the membrane was exposed to x ray film (Hyperfilm-ECL, Amersham Corp.). The blots for the uPAR protein were quantified with the software NIH Image 1.53.

STATISTICS

Data were evaluated by the $\chi^2$ test and the unpaired Student’s t test. Statistical values were considered significant when $p<0.05$.

Results

IN SITU HYBRIDISATION

uPAR mRNA reactivities were scattered throughout the overall, central, and peripheral proliferating region in 30 (30%) of the 100 colorectal adenomas studied: mild dysplasia (6/31; 19%), moderate dysplasia (7/33; 21%), and severe dysplasia (17/36; 47%) (fig 1A; table 1). uPAR mRNA expression was detected mainly in the cytoplasm of dysplastic epithelial cells, being faintly positive or negative in the cytoplasm of stromal cells located in the vicinity of the dysplastic glands (fig 1C). uPAR mRNA positive stromal cells revealed morphological features of inflammatory cells comprising macrophages, neutrophils, and lymphocytes. An accumulation of uPAR mRNA was detected in wholly cancerous tissue, predominantly at the advancing front in 68/80 (85%) invasive carcinomas: Dukes’ stage A (21/29; 72%), stage B (26/28; 93%), and stage C (21/23; 91%) (fig 1E; table 1).

Strong hybridisation signals for uPAR mRNA were detected in the cytoplasm of malignant cells, and faint signals in some stromal cells around malignant glands. Significant increases in the frequency of uPAR mRNA expression were observed in severe dysplasia over that in moderate dysplasia (p<0.05), in Dukes’ stage A invasive carcinoma over that in severe dysplastic adenoma (p<0.05), and in Dukes’ stage B over that in stage A (p<0.05); the differences between adenoma with mild dysplasia and adenoma with moderate dysplasia, and between Dukes’ stage B and stage C
did not however reach statistical significance. No detectable signal was seen in the normal tissue adjacent to the cancerous or adenomatous region. The distribution patterns obtained with two different probes were similar in all cases. No signal was detected with the sense riboprobe in adjacent sections (fig 1B,D,F).

**NORTHERN BLOT ANALYSIS OF uPAR mRNA**

In adenomas with increasing severity of atypia, northern blot analysis showed that 3/12 mild, 4/14 moderate, 5/10 severe dysplasia, five of Dukes’ stage A (5/5), five of stage B (5/5), five of stage C tumours (5/5), and three metastatic colorectal carcinomas of the liver (3/3) contained uPAR mRNA 1.7kb in size (fig 2A; table 1), and that there was a significant correlation between uPAR mRNA level and the progressive state of the adenoma (fig 3). During the increasing severity of atypia in adenoma, although there was no significant difference in uPAR mRNA level between mild and moderate dysplasia, the level was significantly higher in severe dysplasia (1.5-fold) than in moderate dysplasia (p<0.05). Furthermore, the amount of uPAR mRNA was 1.8-fold higher in Dukes’ stage A than in severe dysplastic adenoma (p<0.05) and 1.2-fold higher in Dukes’ stage B than in stage A (p<0.05). The level of uPAR mRNA was, however, not related to later stages of invasive carcinoma, Dukes’ stage B, stage C, or to liver metastasis of colorectal carcinoma. No band for uPAR mRNA was detected in any of the seven normal tissue studies. These results corroborated those of in situ hybridisation.

**WESTERN BLOT ANALYSIS**

Western blot analysis of tissue lysates with anti-uPAR antibody no. 3937 revealed a single protein band of approximately 55 kDa, corresponding to the molecular mass of purified uPAR, in mild (3/12), moderate (3/13), and severe (6/15) dysplasia, in Dukes’ stage A (4/5), stage B (5/5), and stage C (5/5), and in metastatic colorectal carcinomas of the liver (3/3) (fig 2B; table 1). As expected from quantitative analysis of mRNA by northern blotting, uPAR protein contents were related to the state of progression of adenoma and carcinoma (fig 3). In adenomas, the uPAR protein concentration in severe dysplasia was 1.3-fold higher than that in moderate dysplasia (p<0.05), and in invasive carcinoma, the concentration in Dukes’ stage A was 1.8-fold higher than that in severe dysplasia and that in Dukes’ stage B was 1.2-fold higher than that in stage A (p<0.05). There was no clear correlation between mild dysplasia and moderate dysplasia in adenoma or the later stages of invasive carcinoma (Dukes’ stage B, stage C, or liver metastasis of colorectal carcinoma). No band for uPAR protein was detected in seven specimens of normal colon tissues.

**DISCUSSION**

Extracellular proteolytic degradation regulates cancer invasion as well as tissue remodelling under physiological conditions. Numerous clinical and experimental studies have provided evidence of a critical role of the uPA system in cancer invasion and metastasis.17–32 One of the components of this system, uPAR expression...
on the surface of tumour cells, has proved to be central to the invasion process and to tumour progression. Blocking uPAR expression by antisense uPAR mRNA or inactivation of uPAR inhibits invasiveness and metastatic activity of carcinoma cells in vitro and in vivo. uPAR is also involved in angiogenesis and tumour growth. In contrast with carcinomas, the contribution of uPAR in premalignant lesions has received little attention.

Our study showed both the cellular expression and distribution of uPAR mRNA during the progression from colorectal adenomas with mild dysplasia to carcinoma in situ and the manifest invasive cancer revealed by in situ hybridisation and northern blot analysis. In 30% of adenomas, the uPAR gene transcript was scattered in dysplastic epithelial cells. In 85% of invasive carcinomas, strong signals for the uPAR gene transcript were detected mainly in carcinomatous cells, predominantly at the invasive edges of tumours; much weaker signals were detected in stromal cells, mainly inflammatory cells, around adenomatous or carcinomatous glands. Furthermore, immunohistochemical study localised the corresponding antigens to adenomatous dysplastic cells or carcinomatous cells. These findings indicate that the main source of uPAR synthesis is essentially dysplastic epithelial or carcinomatous cells in colorectal neoplasms. It should be noted that this result differs from earlier studies using in situ hybridisation and immunohistochemistry that have suggested that uPAR is produced by stromal, not dysplastic epithelial cells in adenomas.

Similar discrepancies in the distribution of components of the uPA system have been noted between studies by different groups (reviewed in Andreasen et al). In colorectal adenocarcinomas, the majority of which are considered to develop from premalignant adenomatous lesions, expression of uPAR mRNA and protein have been identified mainly as malignant cells similar to most types of carcinoma and in some reports, to stromal cells around cancer cells as well. Furthermore, studies with in vitro assays have also provided evidence of uPAR upregulation in colon cancer cells. These observations confirm our results that premalignant dysplastic epithelial cells, not stromal components, are the predominant sites of uPAR expression in adenomas.

The various expression patterns of the uPA system remain to be elucidated. Several studies have shown that the production sites of uPAR may vary between different tumours of the same tissue depending on the state of differentiation. Tumour progression involves many interactions between cancer cells and extracellular matrices or stromal cells, including inflammatory cells. Infiltrating inflammatory cells represent a potential source of protease activity in tumours. Recent studies with in vitro assays have provided evidence of the important role of the uPA system in cell attachment, migration, and signal transduction, as well as in pericellular proteolysis. uPAR expresses in monocytes/macrophages, PMNs (polymorphonuclear neutrophil leucocytes), fibroblasts, endothelial cells, and keratinocytes in inflammation, wound healing, and angiogenesis; furthermore, uPAR expression can be regulated under the influence of cytokines and growth factors (reviewed in Vassili et al). Such uPAR presence on various types of cells may reflect its multitude of functions under pathological conditions involving cancer invasion and could, therefore, be controlled dynamically. Indeed, uPAR mRNA reactivity was recognised faintly in stromal inflammatory cells in this study. For example, in vitro, endotoxin stimulates uPAR expression in inflammatory cells, and uPAR facilitates their migration; some of the discrepancies in the distribution of uPAR expression in colorectal neoplasms may be due to differences in the state and degree of uPAR synthesis by the inflammatory cells that infiltrate around the neoplastic glands.

The increases of uPA content and proteolytic activity have been reported to associate with the adenoma-carcinoma sequence. In contrast with uPA, it is still unknown when dysplastic cells express the uPAR gene in colorectal carcinogenesis and whether there is a parallel correlation between uPAR expression and the histological grade of dysplasia in premalignant adenomas. Our qualitative and quantitative analyses of mRNA by in situ hybridisation and northern blotting disclosed that uPAR gene expression in dysplastic cells increased in the adenomas with increasing severity of atypia; it increased more significantly in severe dysplasia than in mild or moderate dysplasia. Furthermore, the expression increased more notably in Dukes’ stage A carcinomas than in severe dysplastic adenomas, and in the more invasive Dukes’ stage B carcinomas than in the less advanced Dukes’ stage A carcinomas. Western blot analysis also showed that uPAR protein was coupled to a corresponding increase in uPAR mRNA. These findings suggest possible involvement of uPAR gene upregulation in the invasive behaviour of colorectal cancer. It may be assumed that in the process of the transformation of severely dysplastic epithelium containing carcinoma in situ into invasive carcinoma, cancer cells which upregulate the uPAR gene may acquire invasive phenotypes of both the capability to generate cell surface proteolytic activity by activation of receptor bound uPA and the potential to invade beyond the muscularis mucosae to the serosa and then to metastasise.

In this study, immunohistochemical staining revealed that only 14% of adenomas and 45% of invasive carcinomas displayed immunoreactive signals in both cell membranes and the cytoplasm of dysplastic epithelial or cancer cells, the signals being scattered throughout the adenomas or being most prominent in the invasive region of the cancers. The distribution pattern of the uPA protein was similar to that of uPAR mRNA in adenomatous or carcinomatous tissues; however, the frequency of uPAR protein expression was low compared with that of mRNA. Interestingly, this dissociation between uPAR mRNA and protein...
expression agrees with studies by Pyke et al, which reported that many neoplastic cells show a prominent signal for uPAR mRNA, but do not contain detectable concentrations of uPAR protein in colon cancer. One possible explanation is that uPAR mRNA is not partly translated. As determined by ELISA, however, adenomas show intermediate uPAR concentrations between normal colonic mucosa and carcinomas. Our results by immunoblot analysis showed the expression of uPAR protein in only 12 of 41 adenomas but in 17 of 20 carcinomas. Our results by immunoblot analysis showed the expression of uPAR protein in only 12 of 41 adenomas but in 17 of 20 carcinomas.41 Our results by immunoblot analysis showed the expression of uPAR protein in only 12 of 41 adenomas but in 17 of 20 carcinomas. 

Immunoblot analysis, which is more sensitive than immunostaining, readily reveals uPAR antigenicity in 94% of cancers and in 29% of adenomas. The third and most likely explanation is that the detection of uPAR antigen by immunoblot frequency may be due to the presence of various uPAR molecular forms resulting from the extent of glycosylation, the presence or absence of cleavage and alternatively spliced forms.74–76 The various molecular forms cause the differences of antigenicity detected with monoclonal antibodies. Luther et al have suggested that the differences of immunoreactivity might be explained by the interference of the interaction of the Mabs with receptor bound uPA or with the extent of glycosylation.77 Furthermore, the alternative splicing of uPAR cDNA may partly explain the discrepancies in the distribution of uPAR mRNA.

Broad clinical studies have established that components of the uPA system are a prognostic marker in many malignancies.25–31 Ganesh et al have identified uPAR concentration as a prognostic factor in the comparison of patients with modified Dukes’ stage B versus C in 161 colorectal cancers.32 This result partly disagrees with our inability to detect significant differences in the level of uPAR mRNA or protein between Dukes’ stage B and stage C, or in morbidity or mortality. The disagreement may be a reflection of the small number of cases (15) analysed in the present study, or of the classification difference in the stages of cancer: tumours invading to muscularis propria are classified as Dukes’ A, but as stage B1 according to Dukes’ modified classification.

Taken together, these observations document the contribution of uPAR in colorectal premalignant lesions during cancer progression. We suggest that uPAR expresses essentially in dysplastic epithelial cells in colorectal adenomas and that the expression is upregulated with increasing severity of atypia in adenomas and increases notably during the critical transition from severe dysplastic adenoma to invasive carcinoma. These findings implicate uPAR expression in the invasive and metastatic processes of adenocarcinoma of the colon and rectum.

We thank Dr Erkki Minami, Dr Hiroshi Yoshida, and Dr Masao Shirakawa for kindly providing the adenomatous tissue samples used in this work. The expert technical assistance of Miss Chiyomi Beuchi is also gratefully acknowledged. This work was supported in part by Grants in Aid for Scientific Research (C05807014, 07045706, 08877199, and B2) and the Japanese Research for the Control of Cancer (08877199) from the Ministry of Education, Science, Sports, and Culture, Japan.
Plasminogen activator receptor expression in colorectal neoplasm


Urokinase type plasminogen activator receptor expression in colorectal neoplasms

S Suzuki, Y Hayashi, Y Wang, T Nakamura, Y Morita, K Kawasaki, K Ohta, N Aoyama, S R Kim, H Itoh, Y Kuroda and W F Doe

*Gut* 1998 43: 798-805
doi: 10.1136/gut.43.6.798